Abstract 927: Gut microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma
Abstract
Malignant gliomas are devastating diseases that require new and more effective treatments. To improve clinical outcomes, our laboratories have developed an oncolytic adenovirus armed with the T-cell activator OX40L, named Delta-24-RGDOX. Here, we evaluated changes to gut microbiome in glioma bearing mice treated with viroimmunotherapy. GL261 glioblastoma cells were implanted in the brain of immunocompetent C57BL/6 mice. Then mice were treated...
Paper Details
Title
Abstract 927: Gut microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma
Published Date
Jul 1, 2021
Journal
Volume
81
Pages
927 - 927
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History